Stimulation and Validation of the Pupillary Dilation for the Detection of Pain in Analgosedated Patients Under Mechanically Ventilation in Intensive Care Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-14

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This project has 2 phases. Phase 1: diagnostic test study, to evaluate the efficacy of the variation of pupillary size (PDR) to detect pain in ICU patients regarding to Behavioural Pain Scale (BPS) and ESCID (Conductual Scale Pain Index). Phase 2: controlled and aleatorized clinical trial to evaluate efficacy in PDR monitoring after painful assessed minimum stimulus with the best diagnostic efficiency on phase 1, as a need of analgesia indicator tool.

The sample will be patients over 18 years, sedated and mechanically ventilated, with an initial BPS of 3, RASS between -1 and -4, not able not to communicate , with inform consent signed. Exclusion criteria will be: ophtalmologic pathology and administration of drugs interfering pupillary reflexes. Measurements before/during pain/non-pain situations, aspiration of secretions and calibrated intensity stimulus through the pupilometer Algiscan. The investigators will study association between pain according to BPS/ESCID and pupillary dilatation according to pupillometry and percentage of patients with pain and preanalgesia according to pupillometry and standard clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the ANI Validity on Evaluation of Nociception in State of Hypnosis

NCT02302313

Healthy

COMPLETED NA

Effects of External Ear Stimulation on Pain Perception and Mood

NCT02821741

Pain in Healthy Participants

RECRUITING NA

Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic Blocks

NCT02390323

Nerve; Disorder, Sympathetic

COMPLETED NA

Effects of the Ultra-low Frequencies TENS on the Arousal Circuits

NCT06790459

Pupil Diameter Arousal

COMPLETED NA

Distraction Techniques in Periocular Anesthesia: Tapping vs Vibration

NCT06355817

Anesthetics, Local Blepharoplasty Age-Related Ptosis +6 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Every patient will be subjected to a measured stimulus with a power selected in phase 1 (X mA) and pupillary dilatation will be measured by pupillometry. In those patients showing pupillary size variation over the limit for insufficient analgesia estimated in phase 1 for tracheal suction, additional analgesia will be provided before tracheal suction. In those patients without pain detected by pupillometry, additional anlagesia won´t be provided. In both cases Pupillometry, BPS and ESCID will be measured during tracheal suction to determine whether the patient is in pain or not.

Group Type EXPERIMENTAL

Pupillometer

Intervention Type OTHER

Measurements of pupillary dilatation with pupillometer to administer or not analgesia

Control group

Before tracheal suction and due to medical decision, analgesia following current clinical practice would be administered prophylactically.

Pupillometry, BPS and ESCID will be measured during tracheal suction to determinate whether the patient is in pain or not.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pupillometer

Measurements of pupillary dilatation with pupillometer to administer or not analgesia

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years.
* Analgosedated patients under mechanical ventilation.
* Unable to communicate (verbal or motor).
* Patients with initial BPS of 3, and RASS from -1 to -4.
* Familiar prior informed consent.

Exclusion Criteria

* Patients treated with muscle relaxants.
* Severe Critical Polyneuropathy.
* Pupillary reflex affectation in diabetic patients (diabetic papillopathy,glaucomatous optic neuropathy) or any other pathologies like Adie´s Syndrome, Argyl-Robertson pupil.
* Patients with tansmisible ocular infections.
* Patients with possible injury of the third carnial nerve (Horner´s syndrome) due to injury to the brainstem, cervical cord, cancer of the upper lobe the lung, dissection of the carotid and/or cluster headache.
* Acute cerbrovascular conditions with Glasgow Coma Scale less than 6, or increased intracranial pressure, or pontine base infarction.
* Drugs that interfere with the pupillary reflex (clonidine, dexmedetomidine, metoclopramide, tramadol, droperidol, ketamine, nitrous oxide).
* Patients under metoclopramide, if given 10 minutes prior the measurement of the pupillary reflex (PDR).
* Patients during the first 24 hours after Cardiac Arrest (CRP).
* Severe unestable comorbidity with doses of norepinephrine\> 0.6 microg/kg/min and/or dobutamine\>10 microg/kg/min or drenalin any doses.
* Patients with untreated pheochromocytomas.
* Refuse to participate in the trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No